Next-Gen Modalities, Expertly Enabled

As therapeutic pipelines expand beyond small molecules, novel modalities demand specialized capabilities that can flex from early discovery through clinical and commercial supply. This overview highlights how integrated support across oligonucleotides, peptides, and conjugates can reduce handoffs, shorten timelines, and de‑risk development.

Coverage spans DNA and RNA modalities, including antisense, siRNA, and modified chemistries, alongside linear and complex peptide formats such as cyclic, lipidated, and labeled constructs. Conjugation strategies—ranging from click chemistry to antibody‑ and ligand‑based approaches—enable targeted delivery and next‑generation designs. Across modalities, scalable synthesis platforms are paired with deep analytical expertise, including impurity profiling, structural characterization, and ICH‑compliant method validation.

By combining flexible scale‑up, robust quality systems, and end‑to‑end program governance, this approach supports faster transitions from concept to clinic while maintaining the documentation and control needed for regulatory submissions. The result is greater confidence as novel modalities move toward patients.